William Blair analyst Brandon Vazquez has maintained their bullish stance on EW stock, giving a Buy rating yesterday.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Brandon Vazquez has given his Buy rating due to a combination of factors that highlight Edwards Lifesciences as a strong growth opportunity in the medtech sector. The company’s recent investor day reinforced confidence in its ability to achieve sustained double-digit growth in both revenue and earnings. A key aspect of this optimism is Edwards’s extensive pipeline of clinical data and new products, which are expanding its total addressable market beyond the current transcatheter aortic valve replacement (TAVR) market.
Additionally, the breadth of Edwards’s product portfolio, including repair and replacement options for multiple valves, coupled with robust clinical support, positions the company competitively. This strategic positioning is expected to help Edwards capture more market share in its existing core markets. With healthy end-markets and several growth catalysts in areas like mitral and tricuspid valves, Vazquez believes Edwards is a vital stock for healthcare investors, projecting over 10% EPS growth and maintaining an Outperform rating.
Vazquez covers the Healthcare sector, focusing on stocks such as Ceribell, Inc., Penumbra, and Zoetis. According to TipRanks, Vazquez has an average return of -3.9% and a 40.70% success rate on recommended stocks.
In another report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $103.00 price target.